As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

SNY beats Q1 estimates for earnings, while missing the same for sales. It expects earnings growth to rebound in 2025.

French pharma major Sanofi delivered a set of first-quarter financial results that seemed to satisfy markets Thursday, as its ...

Sanofi SA (NASDAQ:SNY) reported Thursday a first-quarter 2025 business operating income of 2.9 billion euros ($3.06 billion), ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...

Sanofi (SNY) stock and Roche (RHHBY) stock trade flat after the duo reaffirmed 2025 forecasts despite strong Q1 results. Read ...

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

Approval granted for adults and children 12 years and older who remain symptomatic despite antihistamine treatment.

Sales rose 11% to 9.895 billion euros on higher demand for its blockbuster anti-inflammatory drug Dupixent. Sales of Dupixent rose 20% to 3.48 billion euros, slightly up from analysts' expectations of ...

Roche beat first-quarter sales expectations Thursday, while Sanofi's sales report came in mixed. Shares were muted in ...

Sanofi confirms the expectation of a strong rebound in business EPS with growth at a low double-digit percentage at CER (before share buyback)6 • Sanofi intends to complete a share buyback program in ...